Dr Catherine O’Neill, chief executive of SkinBioTherapeutics PLC (LON:SBTX), updates Proactive on progress with their platform - saying it's passed a key safety test.

The SkinBiotix cream was assessed for cellular toxicity and specifically for adverse biological reactions from mammalian cell cultures.

No cytotoxicity was observed; in other words there was no malformation of cells, or cell degeneration.

The data backed up in-house results compiled by the company, which listed on the stock market in April.